Low Dose Naltrexone
Explore whether low-dose naltrexone fits your care. A clinician will review your health history, medicines, and goals before recommending treatment.
Understanding low-dose naltrexone
Low-dose naltrexone (LDN) uses smaller doses of naltrexone than those used for its FDA-approved uses. Clinicians may consider it off-label for selected patients. Off-label means the FDA has not approved the drug for that use.
Research and clinical experience vary by condition. LDN may help some people, but benefits are not certain and results vary. It is not a cure or a replacement for other care you need.
Naltrexone blocks opioid receptors. It can interfere with opioid medicines and may cause severe withdrawal in someone who depends on them. Tell your clinician about all medicines and supplements you take, including opioid pain medicines. Do not stop prescribed medicines on your own.
Your clinician will discuss possible benefits, side effects, interactions, and monitoring. A consultation helps you make an informed choice; it does not guarantee a prescription.
Learn more: FDA: Understanding off-label use.
Conditions to discuss with your clinician
These topics may come up in an LDN consultation. Being listed here does not mean LDN is proven or appropriate for every condition or person.
-
Complex Regional Pain Syndrome/RSD
Diabetic Neuropathy
Migraines
Peripheral neuropathy
Temporomandibular joint disorder
-
Autoimmune hepatitis
Autoimmune enteropathy
Autoimmune pancreatitis
Celiac disease
Churg-Strauss syndrome
Crohn’s disease
Eosinophilic gastroenteritis
Gastritis
Gastrointestinal pemphigoid
Gastroparesis
Gluten sensitivity
Gut dysbiosis
Inflammatory bowel disease (IBD)
Irritable bowel syndrome (IBS)
Lupoid hepatitis
Nonalcoholic steatohepatitis (NASH)
Mesenteric Panniculitis
POEMS syndrome
Polyarteritis nodosa
Primary biliary cirrhosis
Primary sclerosing cholangitis
Pyoderma gangrenosum
Small intestinal bacterial overgrowth (SIBO)
Schnitzler syndrome
Ulcerative colitis (UC)
-
Adult Still's disease
Ankylosing spondylitis
Anti-synthetase syndrome
Arthritis
Chronic fatigue syndrome (CFS)
Chronic recurrent multifocal osteomyelitis (CRMO)
Complement component 2 deficiency – increase risk of lupus
CREST syndrome
Ehlers-Danlos Syndrome (EDS)
Enthesitis-related arthritis
Eosinophilic fasciitis
Fibrodysplasia ossificans progressive
Fibromyalgia
Inclusion body myositis (IBM)
Juvenile arthritis
Juvenile idiopathic arthritis
Juvenile rheumatoid arthritis – Still’s disease
Lupus erythematosus
Majeed syndrome
Mixed connective tissue disease (MCTD)
Morphea myositis
Myalgic Encephalopathy (ME)
Palindromic rheumatism (PR)
Polymyalgia rheumatica
Polymyositis
Psoriatic arthritis
Reactive Arthritis
Reiter's syndrome
Relapsing polychondritis
Retroperitoneal fibrosis
Rheumatic fever
Rheumatoid arthritis
Sarcoidosis
Schnitzler syndrome
Scleroderma
Seropositive arthritis
Sjögren's syndrome
Spondylitis
Spondyloarthropathy
Undifferentiated connective tissue disease (UCTD)
Undifferentiated spondyloarthropathy
-
Alcohol use disorder
Anxiety
Autism
Depersonalization/Derealization Disorder
Depression
Dissociative Disorder
Dissociative identity disorder
General Anxiety Disorder (GAD)
Hypervigilance
Obsessive Compulsive Disorder (OCD)
Opioid withdrawal
Panic Disorder
Phobias
Post-Traumatic Stress Disorder (PTSD)
Postpartum Depression
Premenstrual Dysphoric Disorder (PMDD)
Social Phobia
Stress
Substance abuse disorders
Trichotillomania
-
Alopecia areata
Alopecia universalis
Amyopathic Dermatomyositis
Anti-synthetase syndrome
Atopic allergy
Atopic dermatitis
Autoimmune progesterone dermatitis
Autoimmune urticaria
Bechet’s syndrome
Benign mucosal pemphigoid
Blau syndrome
Bullous pemphigoid
Cicatricial pemphigoid
Cutaneous leukocytoclastic angiitis
Darier Disease
Dego's disease (thrombotic vasculopathy)
Dercum's disease (adiposis dolorosa)
Dermatitis herpetiformis
Dermatomyositis
Diffuse cutaneous systemic sclerosis
Discoid lupus erythematosus
Eczema
Epidermolysis bullosa acquisita
Erythema nodosum
Erythmodermic psoriasis
Essential mixed cryoglobulinemia
Familial cold autoinflammatory syndrome (FCAS)
Frontal Fibrosing Alopecia (FFA)
Hailey-Hailey Disease
Herpes gestationis/pemphigoid gestationis (PG)
Hidradenitis Suppurativa (HS) (Acne Inversa)
Kawasaki disease
Lichen planus
Lichen sclerosus
Linear IgA disease (LAD)
Majeed syndrome
Morphea Mucha-Habermann disease, PLEVA (pityriasis lichenoides et varioliformisacuta)
Myositis
Neonatal lupus
Parry Romberg syndrome
Pemphigus vulgaris
POEMS syndrome
Progesterone dermatitis
Psoriasis
Pyoderma gangrenosum
Schnitzler syndrome
Schulman disease
Subacute cutaneous lupus erythematosus (SCLE)
Sweet's syndrome
Topical Steroid Withdrawal (TSW)
Vitiligo
Vogt-Koyanagi-Harada Disease
-
Addison's disease
Autoimmune polyendocrine syndrome
Cushing's syndrome
Diabetes mellitus type 1
Eosinophilic esophagitis (EoE)
Glycogen storage disorder (GSD VII)
Graves' disease
Hashimoto's thyroiditis
Hypoglycaemia
Hypopituitary or Secondary adrenal insufficiency
Hypothalamic Dysfunction
Hypothyroidism
Juvenile diabetes (Type 1 diabetes)
Ord’s thyroiditis
Pituitary dysfunction
POEMS syndrome
Polyglandular syndromes type I, II, III
Schmidt syndrome
Thyroid eye disease (TED)
Thyroiditis
-
Amyloidosis
Autoimmune angioedema
Common Variable Immunodeficiency
Epstein Barr Virus
IgG4-related sclerosing disease
Juvenile myositis (JM)
Mast cell activation syndrome (MCAS)
Mold toxicity
Pernicious anemia (PA)
Vitiligo
-
Autoimmune oophoritis
Endometriosis
Healthy pregnancy – new concepts
Herpes gestationis/pemphigoid gestationis (PG)
Infertility
PMS (premenstrual syndrome)
Polycystic Ovary Syndrome (PCOS)
Pregnancy
Premenstrual syndrome (PMS)
Progesterone dermatitis
Recurrent vaginitis
Reduced ovarian reserve (Low AMH)
Vaginitis
Vulvodynia
Painful periods (Dysmenorrhea)
-
Anti-GBM/Anti-TBM Nephritis
Autoimmune orchitis
Autoimmune renal neuropathy
Berger's disease - IgA nephropathy
Glomerulonephritis
Goodpasture's syndrome
IgA nephropathy
Interstitial cystitis (IC)
Microscopic polyangiitis (MPA)
POEMS syndrome
Sperm & testicular autoimmunity
Anti-synthetase syndrome
Asthma Churg-Strauss syndrome
Emphysema
Fibrosing alveolitis
Granulomatosis with Polyangiitis (formerly Wegener’s Granulomatosis)
Goodpasture's syndrome
Idiopathic pulmonary fibrosis
POEMS syndrome
Sarcoidosis
Pediatric Disorders: Addison’s disease
Autism
Celiac disease
Congenital heart block
Crohn’s disease
Juvenile arthritis
Juvenile dermatomyositis
Juvenile diabetes (Type 1 diabetes)
Juvenile idiopathic rheumatoid arthritis
Juvenile myositis (JM)
Lupus
Multiple sclerosis (MS)
Neonatal Lupus
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections
Scleroderma
Type 1 diabetes
Ulcerative colitis (UC)
Autoimmune retinopathy
Autoimmune uveitis
Blau syndrome
Cogan's syndrome
Devic’s disease (neuromyelitis optica)
Ligneous conjunctivitis
Miller-Fisher syndrome
Mooren’s ulcer
Neuromyelitis optica
Ocular cicatricial pemphigoid
Optic neuritis
Opsoclonus myoclonus syndrome
Pars planitis (peripheral uveitis)
Scleritis
Susac's syndrome
Sympathetic ophthalmia (SO)
Thyroid eye disease (TED)
Tolosa-Hunt syndrome (THS)
Uveitis
Vogt-Koyanagi-Harada Disease
Adenoid Cystic Carcinoma
Bladder Cancer
Breast Cancer
Carcinoid Colon & Rectal Cancer
Cholangiocarcinoma
Colon Cancer
Esophageal carcinoma
Glioblastoma
Glioma
Hepatoblastoma
Leukemia
Liver cancer
Lung cancer (Non-small cell)
Lymphocytic leukemia (chronic)
Lymphoma (Hodgkin's and Non-Hodgkin's)
Malignant melanoma
Mesothelioma
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Parotid carcinoma
Prostate cancer (untreated)
Renal cell carcinoma
Throat cancer
Uterine cancer
LDN dosing is personal
Follow your prescription and your clinician’s plan. Information on this page does not tell you how to start LDN or change your dose.
Your starting dose, dose changes, and timing depend on your health history, response, and side effects. Your clinician may suggest a gradual increase and follow-up checks.
Keep a short symptom journal and share changes with your care team. Do not increase, split, or change your dose without guidance from your prescriber.
If you have side effects or new symptoms, contact your prescriber for advice. Do not assume symptoms will settle on their own or change your dose based on this page. Seek urgent local care for severe symptoms.
Our LDN Direct Titration Guide provides general education. Use it alongside the plan your clinician gives you.
Patient experiences
These personal accounts describe individual experiences. They do not establish that LDN caused the changes described, and they do not predict or guarantee your results.
LDN has made functioning better. My joint pain is gone, my butterfly rash is gone, I have more energy, more stamina, I can think clearer, and I sleep better. I went from needing half a day to recover from a shower to working a full time job and fully functioning as a single mother. Life altering doesn’t begin to cover it.”
Michelle, Ohio
“LDN’s been my biggest help with MCAD since beginning treatment. It’s the first change that’s allowed me to get foods/supplements back and has significantly expanded my diet, which was previously limited to only a few ingredients. I think it’s also helped with recovery time after exposure to triggers and my gastroparesis, which hasn’t had as many significant episodes since beginning LDN.”
Chelsea, Arizona
“I am taking it for RA, thyroid disease and general inflammation. I am so happy with my results! My pain is gone. Even my lifelong depression is GONE!”
Nick, Washington
“I was diagnosed with fibromyalgia several years ago, and was interested in trying LDN for management of pain. I have not tried any other medications other than ibuprofen and Meloxicam, which were not very helpful. As directed, I titrated the dose of LDN starting with daily 1.5 mg, increasing every 2 weeks. After experimenting with dividing the dose morning and night, I found the best relief from pain and fatigue was with 6 mg twice per day.”
Helen, Georgia